KalVista Pharmaceuticals (NASDAQ:KALV) Trading 4% Higher

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) shot up 4% during trading on Monday . The company traded as high as $13.58 and last traded at $13.56. 12,864 shares were traded during mid-day trading, a decline of 98% from the average session volume of 563,465 shares. The stock had previously closed at $13.04.

Wall Street Analyst Weigh In

KALV has been the topic of a number of recent analyst reports. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a research note on Monday. Needham & Company LLC decreased their target price on shares of KalVista Pharmaceuticals from $35.00 to $32.00 and set a “buy” rating for the company in a research report on Friday.

KalVista Pharmaceuticals Stock Performance

The firm’s 50 day moving average is $11.86 and its 200-day moving average is $12.45. The firm has a market cap of $616.31 million, a price-to-earnings ratio of -4.11 and a beta of 0.91.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Thursday, July 11th. The specialty pharmaceutical company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.29). As a group, research analysts predict that KalVista Pharmaceuticals, Inc. will post -2.65 EPS for the current year.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 7,465 shares of the business’s stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $11.53, for a total value of $86,071.45. Following the transaction, the chief executive officer now directly owns 224,547 shares in the company, valued at $2,589,026.91. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, insider Edward P. Feener sold 8,088 shares of the company’s stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $11.76, for a total transaction of $95,114.88. Following the transaction, the insider now directly owns 72,858 shares in the company, valued at $856,810.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Benjamin L. Palleiko sold 7,465 shares of the stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $11.53, for a total transaction of $86,071.45. Following the completion of the transaction, the chief executive officer now owns 224,547 shares in the company, valued at $2,589,026.91. The disclosure for this sale can be found here. Insiders have sold a total of 37,512 shares of company stock valued at $439,424 over the last quarter. 12.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several large investors have recently bought and sold shares of KALV. Frazier Life Sciences Management L.P. increased its position in shares of KalVista Pharmaceuticals by 11.8% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 3,622,294 shares of the specialty pharmaceutical company’s stock worth $44,373,000 after acquiring an additional 383,435 shares in the last quarter. Vanguard Group Inc. increased its position in shares of KalVista Pharmaceuticals by 9.6% during the third quarter. Vanguard Group Inc. now owns 1,732,489 shares of the specialty pharmaceutical company’s stock worth $16,684,000 after acquiring an additional 151,808 shares in the last quarter. Capital World Investors bought a new stake in shares of KalVista Pharmaceuticals during the first quarter worth $17,370,000. StemPoint Capital LP increased its position in shares of KalVista Pharmaceuticals by 174.4% during the first quarter. StemPoint Capital LP now owns 1,161,060 shares of the specialty pharmaceutical company’s stock worth $13,770,000 after acquiring an additional 737,886 shares in the last quarter. Finally, Rosalind Advisors Inc. boosted its holdings in KalVista Pharmaceuticals by 17.4% during the second quarter. Rosalind Advisors Inc. now owns 337,985 shares of the specialty pharmaceutical company’s stock worth $3,981,000 after purchasing an additional 50,000 shares during the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.